Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omega-3 ethylester concentrate

Drug Profile

Omega-3 ethylester concentrate

Alternative Names: Esapent; Eskim; Lotriga; Lovaza; Omacor; Seacor; TAK-085

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pronova Biocare
  • Developer Ferrer; GlaxoSmithKline; Kuhnil Pharmaceutical Company; Pronova BioPharma; Takeda
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Fatty acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia; Postmyocardial infarction
  • Phase III Cardiovascular disorders
  • Phase I Hyperlipidaemia
  • No development reported Heart failure
  • Discontinued Atrial fibrillation; IgA nephropathy

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 19 Jul 2016 Takeda plans the exploratory LOTUS clinical trial for Hyperlipidaemia (Adjunctive treatment) in Japan (PO) (NCT02839902)
  • 05 Mar 2015 No recent reports on development identified - Preregistration for Heart failure in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top